Back to results
US 2003/0068313 A1Published application
Therapeutic agents for achondroplasia
AssigneeKazuwa Nakao
InventorKazuwa Nakao
Life of this patent
Estimating the term…
Abstract
The present invention aims to provide novel therapeutic agents for achondroplasia caused by mutations in FGFR3. Therapeutic agents for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3), comprising a substance activating guanylyl cyclase B (GC-B) as an active ingredient are disclosed.
Claims5
A therapeutic agent for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3), comprising a substance activating guanylyl cyclase B (GC-B) as an active ingredient.
Dependencies are inferred from the claim text.